The Dermatology Drug market will grow 8% a year to 2008, led by demand for psoriasis treatments, according to the “Dermatology pipeline analysis: a market with room to grow” report by Decision Resources (DR), Waltham, MA. This is largely due to the Food and Drug Administration’s approval of Enbrel, an Amgen-based treatment for adults with moderate-to-severe chronic plaque psoriasis. Medications for atopic dermatitis will also increase, but uticario medications will decline.
Dermatology Drug Market To Grow 8% a Year to 2008
Published November 22, 2005
blog comments powered by Disqus